More news
> All Top Headlines
Expert Opinion
See all »
By Dr. Chepsy Philip Believer’s Church Medical College Hospital Myeloproliferative – Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient
More
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the longer-term follow-up
More
By Dr. Dipesh Uprety Karmanos Cancer Institute Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the standard of
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab, cyclophosphamide, doxorubicin,
MoreVideo News
See all »
Dr. Dipesh Uprety interviewed Dr. Chadi Nabhan about his new book, Toxic Exposure. Watch the video to hear more about the book
More
Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind
More
Dr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phase
MoreNew Approvals
See all »
On April 19, 2023, the U.S. Food and Drug Administration (FDA) approved Polatuzumab Vedotin-Piiq in combination with a rituximab product, cyclophosphamide, doxorubicin,
More
On April 3, 2023, the U.S. Food and Drug Administration approved enfortumab vedontin-ejfv with pembrolizumab for patients with locally advanced or metastatic
More
On March 29, 2023, the U.S. Food and Drug Administration approved pembrolizumab for adult and pediatric patients with unresectable or metastatic solid
More
On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr — a humanized monoclonal antibody that targets
More